Libya is grappling with a severe insulin shortage, a crisis that the National Diabetes Authority attributes to decades of mismanagement, according to its head, Awad Al-Gweiri.
Al-Gweiri stressed that the shortage is not linked to any specific timeframe or individual, but rather to systemic administrative failures dating back to 1996. He warned that all parties involved share responsibility for the worsening national health crisis.
Speaking on Libyan television, Al-Gweiri highlighted that the shortage affects not only standard insulin but also modern formulations vital for children with Type 1 diabetes. He cited prolonged bureaucratic procedures, delays in contract approvals, and slow finalisation of procurement protocols as key factors behind the delayed delivery of essential medicines compared with other countries.
The National Diabetes Authority chief recalled that Libya previously maintained a robust healthcare management system. However, the resignation of Dr. Othman Al-Kadiki from his position triggered a collapse in oversight, exacerbating the crisis.
Al-Gweiri also revealed that the prevalence of diabetes in Libya has reached 17.9%, with around 35% of patients either undiagnosed or non-compliant with treatment. He emphasised that these figures make the current situation particularly alarming, especially for vulnerable populations such as children.
To address the crisis, the National Diabetes Authority has developed a comprehensive plan in coordination with relevant authorities. This strategy includes expediting legal and procurement procedures, liaising with international pharmaceutical companies, and ensuring swift delivery of medicines to patients. Al-Gweiri called for urgent action to protect lives and prevent further deterioration in public health.
